[Splenic capping in the treatment of severe spleen injuries].

Jovanović M, Stanojević G, Jovanović J, Stojanović M

Medicinski pregled1 Jul 2005

PMID16296583DOI10.2298/mpns0508388jPepBankPUB-16296583

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymulin (serum thymic factor).

01AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Efficacy outcome
In dogs with severe spleen injuries, pooled preservation techniques, including sutures with STF, achieved hemostasis in 100%.
In plain wordsIn dogs, the pooled spleen preservation techniques, including STF with sutures, achieved bleeding control in 100%.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicableHemostasis
Study
dogn = 30
Severe spleen injuries treated with splenic preservation techniques
Outcome group
Wound healing · Whole body
Measurements
Hemostasis
100%
All preservation techniques pooled
Source sentences
Summary
The above mentioned techniques were very effective in achieving hemostasis (100%), with no mortality and low rate of postoperative complications--6.7% (1 intrasplenic abscess and 1 adhesive ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Experimental preservation of severe spleen injuries (grade IV), with splenic-capping, was performed in 30 dogs, operated using Ketalar anesthesia.
Summary · context
Additional placement of hemostatic sutures was necessary in 30%, and concomitant application of serum thymic factor (STF) FTA (along with sutures) in 50% of patients.
In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).
Report a problemFND-1629658301
02AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Safety outcome
In dogs with severe spleen injuries, pooled preservation techniques, including STF with sutures, produced no mortality.
In plain wordsIn dogs, no deaths occurred across pooled spleen preservation techniques, including STF with sutures.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicableMortality
Study
dogn = 30
Severe spleen injuries treated with splenic preservation techniques
Outcome group
Mortality · Whole body
Source sentences
Summary
The above mentioned techniques were very effective in achieving hemostasis (100%), with no mortality and low rate of postoperative complications--6.7% (1 intrasplenic abscess and 1 adhesive ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Experimental preservation of severe spleen injuries (grade IV), with splenic-capping, was performed in 30 dogs, operated using Ketalar anesthesia.
Summary · context
Additional placement of hemostatic sutures was necessary in 30%, and concomitant application of serum thymic factor (STF) FTA (along with sutures) in 50% of patients.
In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).
Report a problemFND-1629658302
03AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Safety outcome
In dogs, pooled spleen preservation techniques, including STF with sutures, had a postoperative complication rate of 6.7%.
In plain wordsIn dogs, complications occurred in 6.7% across pooled spleen preservation techniques, including STF with sutures.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicablePostoperative complications
Study
dogn = 30
Severe spleen injuries treated with splenic preservation techniques
Outcome group
Adverse events · Whole body
Measurements
Postoperative complications
6.7%
Pooled techniques
Source sentences
Summary
The above mentioned techniques were very effective in achieving hemostasis (100%), with no mortality and low rate of postoperative complications--6.7% (1 intrasplenic abscess and 1 adhesive ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Experimental preservation of severe spleen injuries (grade IV), with splenic-capping, was performed in 30 dogs, operated using Ketalar anesthesia.
Summary · context
Additional placement of hemostatic sutures was necessary in 30%, and concomitant application of serum thymic factor (STF) FTA (along with sutures) in 50% of patients.
In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).
Report a problemFND-1629658303
04AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Safety outcome
In dogs, pooled spleen preservation techniques, including STF with sutures, produced one intrasplenic abscess.
In plain wordsIn dogs, one spleen abscess occurred across pooled preservation techniques, including STF with sutures.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicableIntrasplenic abscess
Study
dogn = 30
Severe spleen injuries treated with splenic preservation techniques
Outcome group
Adverse events · Whole body
Measurements
Intrasplenic abscess
1 event
Pooled techniques
Source sentences
Summary
The above mentioned techniques were very effective in achieving hemostasis (100%), with no mortality and low rate of postoperative complications--6.7% (1 intrasplenic abscess and 1 adhesive ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Experimental preservation of severe spleen injuries (grade IV), with splenic-capping, was performed in 30 dogs, operated using Ketalar anesthesia.
Summary · context
Additional placement of hemostatic sutures was necessary in 30%, and concomitant application of serum thymic factor (STF) FTA (along with sutures) in 50% of patients.
In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).
Report a problemFND-1629658304
05AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Safety outcome
In dogs, pooled spleen preservation techniques, including STF with sutures, produced one adhesive ileus.
In plain wordsIn dogs, one adhesive bowel obstruction occurred across pooled spleen preservation techniques, including STF with sutures.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicableAdhesive ileus
Study
dogn = 30
Severe spleen injuries treated with splenic preservation techniques
Outcome group
Adverse events · Gastrointestinal
Measurements
Adhesive ileus
1 event
Pooled techniques
Source sentences
Summary
The above mentioned techniques were very effective in achieving hemostasis (100%), with no mortality and low rate of postoperative complications--6.7% (1 intrasplenic abscess and 1 adhesive ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Experimental preservation of severe spleen injuries (grade IV), with splenic-capping, was performed in 30 dogs, operated using Ketalar anesthesia.
Summary · context
Additional placement of hemostatic sutures was necessary in 30%, and concomitant application of serum thymic factor (STF) FTA (along with sutures) in 50% of patients.
In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).
Report a problemFND-1629658305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.